Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 4-59 (IGHV4-59) is a human gene encoding one of the germline variable domains of the immunoglobulin heavy chain. This gene segment contributes to the antigen-binding variable region of immunoglobulins (antibodies), produced by B lymphocytes. The IGHV4-59 segment combines with diversity (D) and joining (J) segments during V(D)J recombination to generate the unique antigen recognition site of each antibody[1][3][4][6]. This process is fundamental to immune system diversity and specificity. IGHV4-59 has been observed in the context of immune responses to HIV-1, particularly in generating antibodies against the Gag protein; it is also associated in the literature with antibody repertoire studies and certain B-cell lymphomas[2]. However, IGHV4-59 itself is not a druggable target but rather a genetic building block used for antibody diversity and immune recognition.
None applicable—the gene segment provides the variable domain used in antibody generation, but mechanisms of action relate to antibodies generated using this segment, not IGHV4-59 itself
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 4-59 (IGHV4-59).